When designing clinical trials for rare and ultra-rare diseases, manufacturers must uncover ways to overcome the geographical and ethical challenges that do not plague chronic disease studies. The article by Mariia Saldova, “Innovating Clinical Trial Designs in Rare and Ultra-Rare Disease,” explores the importance of decentralized clinical trials in a patient population that is difficult to find and explains the benefits to patients seeking access to new therapies. The author describes how one gene therapy company was able to recruit and retain patients using innovative recruitment methods. She also discusses the importance of collaborating with advocacy groups and minority communities to identify and reach new patients.

To read the complete article, visit Med Ad News’ blog, PharmaLive.com.

Learn More
To learn more about how Avalere applies its robust experience in drug development, clinical trial design, and rare disease therapeutics, connect with us.